Skip to main content

Advertisement

SpringerLink
Log in

Does direct-to-consumer advertising affect patients’ choice of pain medications?

  • Published:
Current Pain and Headache Reports Aims and scope Submit manuscript

Abstract

In the United States, direct-to-consumer advertising (DTCA) has grown rapidly to promote prescription medications, including analgesics. Few studies in the literature directly examine the association between DTCA and patients’ choice of pain medications. This article discusses how DTCA affects such choice from a behavioral perspective, because DTCA-prompted behaviors are important indicators of DTCA’s influence. After DTCA exposure, patients may request prescriptions, seek further medication information, and ask about advertised conditions. Patients who suffer from pain may seek more communication with their health care providers because they are cautious about the information quality of DTCA, mainly because of the recall of rofecoxib (Vioxx; Merck, Whitehouse Station, NJ). However, the availability and DTCA of over-the-counter analgesics complicate their treatment choice. Patients could use DTCA as a tool to launch health communication and make an informed treatment choice with the guidance of their health care providers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Draft guidance for industry consumer-directed broadcast advertisements: availability. Fed Regist 1997, 62:43171–43173.

  2. IMS Health, Competitive Media Reporting, June 2004. As cited in Vogt DU. Direct-to-consumer advertising of prescription drugs. Washington, DC: Congressional Research Service, Library of Congress; March 25, 2005.

    Google Scholar 

  3. Nielson Monitor-Plus: Med Ad News: DTC takes a back seat. Available at: http://www.pharmalive.com/magazines/medad/view.cfm?articleID=3522. Accessed June 2007.

  4. Weissman JS, Blumenthal D, Silk AJ, et al.: Consumers’ reports on the health effects of direct-to-consumer drug advertising. Health Aff 2003, W3:82–95.

    Google Scholar 

  5. International Association for the Study of Pain: Pain terminology. Available at: http://www.iasp-pain.org. Accessed June 2007.

  6. Health, United States, 2006: With Chartbook on Trends in the Health of Americans. Hyattsville, MD: National Center for Health Statistics; 2006.

  7. Pain: Current Understanding of Assessment, Management, and Treatments. Reston, VA: National Pharmaceutical Council Inc. and Joint Commission on Accreditation of Healthcare Organizations; 2001.

  8. Moncavage M: DTC review today: a changing environment. Presented at FDLI’s Advertising and Promotion Conference. September 12, 2002. Available at: http://www.fda.gov/cder/ddmac/presentations.htm. Accessed March 2003.

  9. Caudill-Slosberg MA, Schwartz LM, Woloshin S: Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000. Pain 2004, 109:514–519.

    Article  PubMed  Google Scholar 

  10. Peck P: Merck issues worldwide recall of Vioxx [press release]. New York: United Press International; September 30, 2004.

    Google Scholar 

  11. Prevention: National survey of consumer reactions to direct-to-consumer advertising. Emmaus, PA: Rodale Press; 1998.

  12. Time: Consumer and physician attitudes towards direct-to-consumer advertising (consumer survey). New York: Time Inc.; 1998.

  13. Prevention: International survey on wellness and consumer reactions to direct-to-consumer advertising of prescription drugs. Emmaus, PA: Rodale Press; 2000.

  14. Aikin KJ, Swasy JL, Braman AC: Patient and Physician Attitudes and Behaviors Associated with DTC Promotion of Prescription Drugs: Summary of FDA Survey Research Results. Final Report. Washington, DC: US Food and Drug Administration; 2004.

    Google Scholar 

  15. Prevention: Seventh annual survey: consumer reaction to direct-to-consumer advertising of prescription medicines. Emmaus, PA: Rodale Press; 2004.

  16. Prescription Drugs and Mass Media Advertising, 2000: A Research Report. Washington, DC: National Institute of Health Care Management Foundation; 2001.

  17. IMS Health: Top-line industry data, 2002: leading 20 therapeutic classes by total U.S. dispensed prescriptions, 2002. Available at: http://www.imshealth.com. Accessed March 2003.

  18. Liu Y: Patients’ Further Drug Information Seeking after Seeing/Hearing Direct-to-Consumer Advertisements of Prescription Drugs [master’s thesis]. Iowa City, IA: University of Iowa; 2004.

    Google Scholar 

  19. Bower KN, Frail D, Twohig PL, et al.: What influences seniors’ choice of medications for osteoarthritis?: Qualitative inquiry. Can Fam Physician 2006, 52:342–343.

    PubMed  Google Scholar 

  20. Spence MM, Teleki SS, Cheetham TC, et al.: Direct-to-consumer advertising of COX-2 inhibitors: effect on appropriateness of prescribing. Med Care Res Rev 2005, 62:544–559.

    Article  PubMed  Google Scholar 

  21. Bradford WD, Kleit AN, Nietert PJ, et al.: How direct-to-consumer television advertising for osteoarthritis drugs affects physicians’ prescribing behavior. Health Aff 2006, 25:1371–1377.

    Article  Google Scholar 

  22. Free rein for drug ads? A slowdown in FDA review has left consumers more vulnerable to misleading messages. Consum Rep 2003, 68:33–37.

  23. Carbonell M: 10th Annual National Survey on Consumer Reaction to Direct-to-Consumer (DTC) Pharmaceutical Advertising Reveals #1 Action Taken After Seeing DTC Ad: Information Seeking. Available at: http://www.welchmedia.com/ news/article_863.shtml. Accessed June 2007.

  24. Letter to G.D. Searle & Co. NDA 20-998 Celebrex (celecoxib) capsules, NDA 19-908 Ambien (zolpidem tartrate) tablets MACMIS ID #8518. Washington, DC: US Food and Drug Administration; 2000.

  25. Letter to G. D. Searle & Co. NDA 20-998 Celebrex (celecoxib) capsules MACMIS ID #9514. Washington, DC: US Food and Drug Administration; 2000.

  26. Letter to Merck & Co Inc. NDA 21-042 Vioxx (rofecoxib) tablets MACMIS ID #9456. Washington, DC: US Food and Drug Administration; 2001.

  27. Pfizer pulling ads for Celebrex. Available at: http://money.cnn.com/2004/12/20/news/celebrex/index.htm. Accessed December 2004.

  28. Liu Y, Doucette WR, Farris KB, Nayakankuppam D: Drug information seeking intention and behavior after exposure to direct-to-consumer advertisement (DTCA) of prescription drugs. Res Social Adm Pharm 2005, 1:251–269.

    PubMed  Google Scholar 

  29. Prevention: Fifth annual survey: consumer reaction to direct-to-consumer (DTC) advertising of prescription medicines: DTC advertising and self-care, honoring requests for prescription medicines. Emmaus, PA: Rodale Press; 2001.

  30. Understanding the Effects of Direct-to-Consumer Prescription Drug Advertising. Melo Park, CA: Kaiser Family Foundation; 2001.

  31. Prevention: Year two: a national survey of consumer reactions to direct-to-consumer advertising. Emmaus, PA: Rodale Press; 1999.

  32. Bell RA, Kravitz RL, Wilkes MS: Direct-to-consumer prescription drug advertising and the public. J Gen Intern Med 1999, 14:651–657.

    Article  CAS  PubMed  Google Scholar 

  33. Berndt ER: The United States’ experience with direct-to-consumer advertising of prescription drugs: what have we learned? In Promoting and Coping with Pharmaceutical Innovation: An International Perspective. Edited by Sloan FA, Hsieh C. London: Cambridge University Press; In press.

  34. Sheftell F, Dodick D, Cady R: Direct-to-consumer advertising of OTC agents under current FTC regulations: concerns and comment. Headache 2001, 41:534–536.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. S518 PHAR, College of Pharmacy, The University of Iowa, Iowa City, IA, 52242, USA

    William R. Doucette

Authors
  1. Yifei Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William R. Doucette
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William R. Doucette.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liu, Y., Doucette, W.R. Does direct-to-consumer advertising affect patients’ choice of pain medications?. Current Science Inc 12, 89–93 (2008). https://doi.org/10.1007/s11916-008-0017-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11916-008-0017-2

Keywords

Search

Navigation